Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia

• Published in: Journal of the advanced practitioner in oncology 2019-07, Vol.10 (5), p.494-500
• Main Authors: Merchant, Shelby L, Culos, Kathryn, Wyatt, Houston
• Format: Article
• Language: English
• Subjects: Prescriber's Corner
• ISSN: 2150-0878; 2150-0886
• DOI: 10.6004/jadpro.2019.10.5.7

There is no standard therapy for refractory acute myeloid leukemia (AML), but several salvage therapies are available (National Comprehensive Cancer Network [NCCN], 2018). Recently, there have been major developments in the treatment of AML focusing on the development of targeted and novel therapies. Ivosidenib is the first approved oral, targeted, small-molecule inhibitor of the isocitrate dehydrogenase 1 ( ) mutation seen in AML. mutations have been associated with significantly worse outcomes in disease-free survival, relapse-free survival, and overall survival (NCCN, 2018). This article reviews the clinical trials and dose escalation studies that led to the U.S. Food & Drug Administration approval for ivosidenib in patients with relapsed or refractory AML with a susceptible mutation. Patient counseling and monitoring, including dosing and administration, are important steps that advanced practitioners should be aware of. The mechanism of action and pharmacokinetic information for ivosidenib is discussed, as well as recommendations for drug-drug interaction management. Adverse events and monitoring parameters are addressed in detail, as well as how to interrupt and resume treatment due to adverse events.